@article{oai:repo.qst.go.jp:00046737,
 author = {Ohkubo, Yu and Ohno, Tatsuya and Noda, Shin-ei and Kubo, Nobuteru and Nakagawa, Akiko and Kawahara, Masahiro and Abe, Takanori and Kiyohara, Hiroki and Wakatsuki, Masaru and Nakano, Takashi and 大久保 悠 and 大野 達也 and 清原 浩樹 and 若月 優 and 中野 隆史},
 issue = {6},
 journal = {Journal of radiation research},
 month = {Nov},
 note = {The purpose of this study was to evaluate interfractional changes of the minimum dose delivered to 90% of the high-risk clinical target volume (HR-CTV D90) and D2cc of the bladder and rectum during brachytherapy for uterine cervical cancer patients. A total of 52 patients received external beam radiotherapy and high-dose-rate intracavitary brachytherapy (ICBT). For each of four ICBT applications, a pelvic CT scan was performed and the HR-CTV was delineated. Retrospectively, these patients were divided into two groups: (i) the standard dose group with 6 Gy to point A in each ICBT, and (ii) the adaptive dose group with a modified dose to point A to cover the HR-CTV with the 6-Gy isodose line as much as possible. The HR-CTV D90 was assessed in every session, and analyzed as interfractional changes. In the standard dose group, the interfractional changes of the HR-CTV D90 showed a linear increase from the first to the third of the four ICBT (average 6.1, 6.6, 7.0 and 7.1 Gy, respectively). In contrast, those of the adaptive dose group remained almost constant (average 7.2, 7.2, 7.3 and 7.4 Gy, respectively). Especially, in the case of a large HR-CTV volume (≥35 cm(3)) at first ICBT, the total HR-CTV D90 of the adaptive dose group with brachytherapy was significantly higher than that of the standard dose group. There were no significant differences in total D2cc in bladder and rectum between the two groups. Image-guided adaptive brachytherapy based on interfractional tumor volume change improves the dose to the HR-CTV while keeping rectal and bladder doses within acceptable levels.},
 title = {Interfractional change of high-risk CTV D90 during image-guided brachytherapy for uterine cervical cancer.},
 volume = {54},
 year = {2013}
}